Loading…
avatar for Barbara Troupin

Barbara Troupin

Equillium
Independent Director
Barbara Troupin, M.D., MBA, has served as a member of the Equillium (NASDAQ:EQ) Board and Nominating and Governance committee of the board since February 2022. Prior, Dr. Troupin was the Senior Vice President, Medical Affairs at MyoKardia, Inc., a publicly held biopharmaceutical company, from 2020 until 2021, where she was responsible for launch preparation in the United States and EU through the time of MyoKardia’s acquisition by and integration into Bristol Myers Squibb. Prior to joining MyoKardia, Dr. Troupin was the Chief Medical Officer of ERX Pharmaceuticals, a privately held pharmaceutical company, from 2018 until 2019. Prior to that, Dr. Troupin was with Aquinox Pharmaceuticals, Inc., a publicly held pharmaceutical company, as the Chief Medical Officer, Vice President of Clinical Development and Regulatory Affairs between 2016 and 2018. From 2014 to 2016, Dr. Troupin was Senior Vice President, Chief Medical Officer at Apricus Biosciences, Inc, a publicly held biopharmaceutical company. Prior to joining Apricus, Dr. Troupin held positions of increasing responsibility with VIVUS, Inc., a publicly-held pharmaceutical company, across Clinical Development and Medical Affairs from 2006 – 2014, culminating in her role as a Vice President in Medical Affairs.

She is an enthusiastic company builder, fundraiser, and strategist. And in the last several years, she has taken both formal and informal roles in coaching and mentoring executive women as they advance their careers in the life sciences. Dr. Troupin received her Doctorate in Medicine from the University of Pennsylvania School of Medicine where she also completed her M.B.A from the Wharton School of Business, with an emphasis in health care management. She holds a B.A. in Biochemistry and Cell Biology from the University of California San Diego.